SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer from parp Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr. Susana Banerjee spoke to ecancer about the findings of the SOLO1 trial presented at ESMO 2020.nnShe first talked about the rationale behind using a PARP inhibitor (olaparib), for maintenance treatment of patients with newly diagnosed ovarian cancer and BRCA mutation.nnDr Banerjee then went on to explain how the results of the treatment group were better than the placebo group and how the findings of this study can impact the current ovarian cancer treatment.nnSign up to ecancer for free to r
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)